The collaboration will use Google Cloud’s cloud data architecture and machine learning to expand the capabilities of Asensus’ performance-guided surgery framework
ISU is a real-time intraoperative surgical image analytics platform. (Credit: Marcel Scholte on Unsplash)
US-based Asensus Surgical has entered into a collaboration with Google Cloud to integrate the latter’s secure cloud data architecture and machine learning (ML) with the Asensus surgical robot platform.
The multi-year partnership is expected to further expand the capabilities of Asensus Surgical’s Performance-Guided Surgery (PGS) framework through its Intelligent Surgical Unit (ISU).
PGS has been designed to increase accuracy and efficiency during procedures, help surgeons avoid complications, and enhance patient outcomes.
Asensus Surgical president and CEO Anthony Fernando said: “We are thrilled to be collaborating with Google Cloud to realise and scale our Performance Guidance Surgery capabilities, by leveraging the data collected by our state-of-the-art ISU technology in conjunction with Google Cloud’s leading machine learning technologies and cloud architecture.
“For several years, we have been pioneering digital surgical capabilities to provide surgeons with the novel, real-time intraoperative digital tools and clinical intelligence.
“This collaboration to better capture clinical performance data and apply augmented intelligence capabilities to provide clinical insight will ultimately drive consistently superior outcomes for patients.”
The ISU is a platform for real-time intraoperative surgical image analytics that uses augmented intelligence.
Asensus said that ISU lowers surgical variability and offers tools to lessen a surgeon’s cognitive fatigue while gathering clinical data of the operation.
The company has plans to offer client access portals and performance dashboards for doctors and hospitals. Asensus said that Google Cloud’s secure cloud data architecture then collects this data.
The US-based firm will use Google Cloud’s machine learning capabilities to evaluate the data and provide clinical intelligence that hospitals and surgeons can use.
Additionally, the company can enhance the software in the ISU to provide improved intra-operative clinical insight.
For the ISU, machine vision capabilities were approved by the US Food and Drug Administration (FDA) in September 2021.
Asensus earned the CE designation for its surgical robot’s development of machine vision capabilities last month. Currently, the organisation provides increased ISU capabilities in the US, Japan, and Europe.